spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

BioGenes Celebrates 25 Years of Excellence in Quality Control of Biotherapeutics

BioGenes

BioGenes GmbH, specializing in ELISA development and production, is celebrating its 25-year anniversary

Berlin, Germany, July 25, 2017 / B3C newswire/ -- BioGenes GmbH, specializing in ELISA development and production, is celebrating its 25-year anniversary. In 1992 the scientists Dr. Alexander Knoll and Dr. Sergej Ovodov set out with a vision to provide services and kits for the quality control of biotherapeutics. Over the course of the last 25 years, BioGenes’s vision has become a reality. BioGenes has grown from a small niche start-up firm providing antibody services to a worldwide leading provider of host cell protein (HCP) assays, customized ELISA development and analytical services.

Company founder and CEO Dr. Alexander Knoll remarked: "This is an incredible milestone for our company. The company has achieved this success through the hard work, passion, and dedication of our team members and our culture of customer service that exists throughout the entire organization. I’m proud to say that our teams consistently exceed client expectations by providing the most efficient, and proactive services to each and every project.”

"To this day BioGenes is still driven by the entrepreneurial spirit of our founders, which has enabled us to constantly expand our offering portfolio," said Dagmar Schwertner, Marketing & Sales Director, who has been with the company for 23 years. "In the fall, BioGenes will be launching a new product for immunogenicity testing.” As of today, BioGenes’ offerings include:

1. Customized ELISA Development
2. Multi-product (platform) and specific HCP assays
3. Generic HCP ELISAs (360-HCP assays for CHO cells and E.coli)
4. Customized Antibodies (incl. anti-idiotypic antibodies)
5. Analytical Services (2D DIGE, 2D Western Blot, HCP coverage determination etc.)

In its 25 years, BioGenes has delivered thousands of projects to our customers. Find out more about BioGenes at www.BioGenes.de
phone +49 (0)30 6576 2396
web www.biogenes.de/
email Köpenicker Straße 325, D-12555 Berlin, Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Horizon Discovery Partners with Sophia Genetics on NGS Reference Standards for Oncology Applications


More info >>


White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

Industry Events

6th Annual Cancer Vaccines Conference

27-28 September 2017, Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies. SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement